Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466763 | 1.00 | LMNA (0.50) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL7431162 | 0.82 | ADRA2C (0.57) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL7431159 | 0.82 | ADRA2C (0.57) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL15984955 | 0.82 | LMNA (0.48) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL28717180 | 0.80 | LMNA (0.47) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL28717182 | 0.80 | LMNA (0.47) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL19625534 | 0.79 | CA1 (0.52) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL13957303 | 0.79 | ADRA2C (0.48) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL10346709 | 0.79 | CA1 (0.52) | LMNAMAPK1CA1CA2CYP2D6 | |
| SCHEMBL10346708 | 0.79 | CA1 (0.52) | LMNAMAPK1CA1CA2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559312-B1 | REACTION PRODUCTS OF CATECHOL COMPOUNDS AND FUNCTIONALIZED CO-REACTANT COMPOUNDS FOR METAL PRETREATMENT APPLICATIONS | HENKEL AG & CO KGAA (DE) | 2024-04-24 | — | — | EP | claimed |
| US-10844421-B2 | Composition from lobster hemocyte extracts for detection of lipopolysaccharides, peptidoglycans and 1,3-beta-D-glucans | CENTRO DE INVESTIGACION Y DESARROLLO DE MEDICAMENTOS (CIDEM) (CU) | 2020-11-24 | — | — | US | claimed |
| EP-3559312-A1 | REACTION PRODUCTS OF CATECHOL COMPOUNDS AND FUNCTIONALIZED CO-REACTANT COMPOUNDS FOR METAL PRETREATMENT APPLICATIONS | Henkel AG & Co. KGaA (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20190301023-A1 | REACTION PRODUCTS OF CATECHOL COMPOUNDS AND FUNCTIONALIZED CO-REACTANT COMPOUNDS FOR METAL PRETREATMENT APPLICATIONS | HENKEL AG & CO. KGAA (DE) | 2019-10-03 | — | — | US | claimed |
| US-20180340206-A1 | COMPOSITION FROM LOBSTER HEMOCYTE EXTRACTS FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3-BETA-D-GLUCANS | CENTRO DE INVESTIG Y DESARROLLO DE MEDICAMENTOS CIDEM (CU) | 2018-11-29 | — | — | US | claimed |
| CN-107880294-A | Sulfonated poly aryl ether ketone sulfone containing amino/amino-acid functional inorganic particulate compoiste proton exchange film | 长春工业大学 | 2018-04-06 | — | — | CN | claimed |
| CN-1929829-B | (S) -2-N-propylamino-5-hydroxytetraline as D3 agonist | SANOL ARZNEI SCHWARZ GMBH | 2010-12-15 | — | — | CN | claimed |
| CN-101532046-A | Site-specific incorporation of redox active amino acids into proteins | SCRIPPS RESEARCH INST | 2009-09-16 | — | — | CN | claimed |
| JP-9149784-A | — | — | None | — | — | JP | disclosed |
| US-12458705-B2 | Antibody-oligonucleotide conjugates | ANGIEX, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | ANGIEX, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4559928-A2 | CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF | The Scripps Research Institute (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250152730-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | ANGIEX, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| CN-1192746-A | Peptide derivatives and angiotensin IV receptor agonists | SAGAMI CHEM RES (JP) | 1998-09-09 | — | — | CN | disclosed |
| JP-H09149784-A | SENSOR FOR DETERMINING PROTEASE ACTIVITY | NEW JAPAN RADIO CO LTD | 1997-06-10 | — | — | JP | disclosed |
| EP-0136996-B1 | STABILIZATION OF L-PHENYLALANINE AMMONIA-LYASE ENZYME | Monsanto Company (US) | 1990-04-11 | — | — | EP | disclosed |
| US-4562151-A | SYNTHESIZING PHENYLALANINES FROM CINNAMIC OR ACRYLIC ACID DERIVATIVES USING A POLYHYDRIC ALCOHOL OR ETHYLENE OXIDE ADDUCT PROMOTER | MONSANTO COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0136996-A2 | Stabilization of L-phenylalanine ammonia-lyase enzyme | Monsanto Company (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | TM9SF4, TM9SF2, TM9SF3 | LMNA 2873/4885MAPK1 4662/4885CA1 3036/4885 |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | LMNA 4576/4885MAPK1 4628/4885CA1 2904/4885 |
| US-12458705-B2 | Antibody-oligonucleotide conjugates | TM9SF4, TMSB4X, IGSF11 | LMNA 2745/4885MAPK1 4629/4885CA1 2747/4885 |
| US-20250152730-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | TM9SF4, TM9SF2, TMPRSS4 | LMNA 2171/4885MAPK1 4409/4885CA1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.